Part II
Vaneeta M. Sheth, MD,a and Amit G. Pandya, MDb
Boston, Massachusetts, and Dallas, Texas
CME INSTRUCTIONS
The following is a journal-based CME activity presented by the American
Academy of Dermatology and is made up of four phases:
1. Reading of the CME Information (delineated below)
2. Reading of the Source Article
3. Achievement of a 70% or higher on the online Case-based Post Test
4. Completion of the Journal CME Evaluation
CME INFORMATION AND DISCLOSURES
Statement of Need:
The American Academy of Dermatology bases its CME activities on the
Academys core curriculum, identied professional practice gaps, the
educational needs which underlie these gaps, and emerging clinical
research ndings. Learners should reect upon clinical and scientic
information presented in the article and determine the need for further
study.
Target Audience:
Dermatologists and others involved in the delivery of dermatologic care.
Accreditation
The American Academy of Dermatology is accredited by the
Accreditation Council for Continuing Medical Education to provide
continuing medical education for physicians.
AMA PRA Credit Designation
The American Academy of Dermatology designates this journal-based
CME activity for a maximum of 1 AMA PRA Category 1 Credits.
Physicians should claim only the credit commensurate with the extent of
their participation in the activity.
AAD Recognized Credit
This journal-based CME activity is recognized by the American Academy
of Dermatology for 1 AAD Recognized Category 1 CME Credits and may
be used toward the American Academy of Dermatologys Continuing
Medical Education Award.
Disclaimer:
The American Academy of Dermatology is not responsible for statements made by the author(s).
Statements or opinions expressed in this activity reect the views of the author(s) and do not reect
the ofcial policy of the American Academy of Dermatology. The information provided in this CME
activity is for continuing education purposes only and is not meant to substitute for the independent
medical judgment of a healthcare provider relative to the diagnostic, management and treatment
options of a specic patients medical condition.
Disclosures
Editors
The editors involved with this CME activity and all content validation/
peer reviewers of this journal-based CME activity have reported no
relevant nancial relationships with commercial interest(s).
Authors
Dr. Pandya has been an investigator and consultant for Galderma
Laboratories within the last 5 years and has received grants and
honoraria for these services. Dr. Sheth reported no relevant nancial
relationships with commercial interest(s).
Planners
Matthew Zirwas, MD, served as a peer reviewer for this CME activity and
is a speaker and consultant for Coria Laboratories and has received
honoraria for these services. He is also a consultant for Onset
Therapeutics and has received honorarium for this service. The other
planners involved with this journal-based CME activity have reported no
relevant nancial relationships. The editorial and education staff involved with this journal-based CME activity have reported no relevant
nancial relationships with commercial interest(s).
Resolution of Conflicts of Interest
In accordance with the ACCME Standards for Commercial Support of
CME, the American Academy of Dermatology has implemented mechanisms, prior to the planning and implementation of this Journal-based
CME activity, to identify and mitigate conicts of interest for all individuals in a position to control the content of this Journal-based CME activity.
Learning Objectives
After completing this learning activity, participants should be able to list
the various treatment options available for melasma and describe their
respective efcacy, side effect proles, and risks and benets; and
develop an individualized, evidence-based treatment plan for patients
with melasma.
Date of release: October 2011
Expiration date: October 2012
2010 by the American Academy of Dermatology, Inc.
doi:10.1016/j.jaad.2011.06.001
Several methods of treatment are available to patients with melasma. First-line therapy usually consists of
topical compounds that affect the pigment production pathway, broad-spectrum photoprotection, and
camouage. Second-line therapy often consists of the addition of chemical peels, although these must be
used cautiously in patients with darker skin. Laser and light therapies represent potentially promising
options for patients who are refractory to other modalities, but also carry a signicant risk of worsening the
disease. A thorough understanding of the risks and benets of various therapeutic options is crucial in
selecting the best treatment. ( J Am Acad Dermatol 2011;65:699-714.)
Key Words: chemical peels; chloasma; hydroquinone; laser therapy; melasma; pigmentation.
699
J AM ACAD DERMATOL
OCTOBER 2011
Melasma has traditionally been treated with a commelasma and in enhancing the efficacy of
bination of photoprotection, avoidance of trigger facother topical therapies once melasma has
tors, and topical depigmenting agents with varying
developed
d Camouflage makeup can be an important
degrees of success. New pathways involved in pigment
production are being studied as targets for topical
component of melasma treatment
therapy. Of late, there has also been a signicant
Several studies have shown that light from both
increase in the types of laser and light technologies
the
ultraviolet (UV) and even the visible spectrum
available for the treatment of
can
induce
pigmentary
disorders of hyperpigmentachanges
in
the
skin,
includCAPSULE SUMMARY
tion. While multiple options
ing
in
Fitzpatrick
skin
photocurrently exist to help treat
2,3
Topical
treatment
of
melasma
includes
Immediate
types
IV
to
VI.
melasma, some of these therahydroquinone, retinoids, chemical peels,
pigment darkening caused
pies have come under increasand
many
other
less
well
studied
by the redistribution and oxing scrutiny, underscoring the
compounds.
idation of preexisting melaneed for more research into
nin occurs after low-dose
The evidence for improvement with laser
the pathogenesis and treatultraviolet A (UVA) exposure
therapy is mixed with a significant
ment of melasma.
and usually fades after 2
potential for worsening.
hours.4 Persistent pigment
TREATMENT OPTIONS
Newer topical agents and laser
darkening lasts up to 24
FOR MELASMA
technologies represent promising
hours and occurs after higher
The treatment of meoptions for therapy, especially in
doses of UVA exposure.
lasma includes topical fortreatment-resistant patients.
Delayed tanning can occur
mulations, chemical peels,
from either UVA or UVB exlasers, and light sources.
posure
and
is
caused
by melanin synthesis. To
While no single therapy has proven to be of
investigate
if
broad-spectrum
sun protection could
benet to all patients as the sole therapy, combibe
used
to
inhibit
the
onset
of
melasma,
Lakhdar et al5
nations of modalities can be used to optimize
enrolled 200 Moroccan women who were less than 3
management in difcult cases. Levels of evidence
months pregnant and gave them a sunscreen with a
for the trials presented below are provided for
sun protection factor (SPF) of 501 and a UVA
each treatment modality based on guidelines
protection factor of 28 (Anthelios; La Roche-Posay
adapted from the US Preventive Services Task
1
LOreal, Clichy, France) to use every 2 hours during
Force on health care. In this system, a rating of
the day, regardless of sun exposure.5 Five of the 185
I means that the evidence is obtained from at least
women (2.7%) who completed the 12-month trial
one properly designed, randomized controlled
developed melasma during pregnancy. Notably, the
trial, and a rating of A means there is good
same investigators reported a 53% prevalence of
evidence to support the use of the procedure
melasma with pregnancy in a similar population in
(Appendix).
an earlier study.6 Eight of 12 patients with preexisting
melasma improved with the sunscreen (level of
SUNSCREENS AND CAMOUFLAGE FOR
evidence, II-iii). Broad-spectrum sun protection has
MELASMA
also been shown to enhance the efficacy of hydroKey points
quinone.7 A double blind study examining the
d Ultraviolet and visible light can induce meldifference in efficacy between patients using a
anin formation
hydroquinone-containing agent with either vehicle
d The regular use of broad spectrum sunor broad-spectrum sun protection found that 96.2%
screen is effective both in preventing
of patients using concomitant sun protection showed
improvement versus 80.7% of patients using hydroFrom the Departments of Dermatology at Brigham and Womens
quinone alone (level of evidence, II-i). A recent study
Hospital,a Harvard Medical School, and the University of Texas
revealed that visible light can produce significant
Southwestern Medical Center,b Dallas.
pigmentation in normal skin, a finding that may be
Funding sources: None.
important in the pathogenesis of melasma.3
Reprints not available from the authors.
With the currently available data, a broadCorrespondence to: Amit G. Pandya, MD, Department of
Dermatology, The University of Texas Southwestern Medical
spectrum UVA- and UVB-protective sunscreen with
Center, 5323 Harry Hines Blvd, Dallas, TX 75390-9190. E-mail:
an SPF of at least 30 along with a physical block, such
amit.pandya@utsouthwestern.edu.
as titanium dioxide or zinc oxide, should be used by
d
0190-9622/$36.00
J AM ACAD DERMATOL
PHENOLIC COMPOUNDS
Key points
Hydroquinone, a tyrosinase inhibitor, has
been extensively researched and found to be
very effective in treating disorders of
hyperpigmentation
d While controversy exists regarding the use
of hydroquinone, a review of the literature
indicates that hydroquinone is safe as a topical agent for melasma
Hydroquinone: The evidence and the
controversy
d
Tyrosinase inhibition
Stimulation of keratinocyte
turnover
Reduction in melanosome
transfer
Interaction with copper
Inhibition of melanosome
maturation
Inhibition of proteaseactivated receptor 2
Inhibition of plasmin
Reduction of alpha
melanocyte-stimulating
hormoneeinduced
melanin production
Compound
Hydroquinone
Mequinol
Azelaic acid
Arbutin and deoxyarbutin
Licorice extract
Rucinol
Resveratrol
4-hydroxy-anisole
2,5-dimethyl-4-hydroxy3(2H )-furanone
N-acetyl glucosamine
Retinoids
Retinoids, soybean trypsin
inhibitor
Kojic acid
Ascorbic acid
Arbutin and deoxyarbutin
Soybean trypsin inhibitor
Tranexamic acid
Beta-carotene
J AM ACAD DERMATOL
OCTOBER 2011
J AM ACAD DERMATOL
RETINOIDS
Key points
d
Tretinoin is an effective treatment for melasma but often causes irritation and usually
requires months to show improvement as
monotherapy
Adapalene may be an alternative retinoid in
patients who cannot tolerate tretinoin
COMBINATION PRODUCTS
Key points
d
J AM ACAD DERMATOL
OCTOBER 2011
J AM ACAD DERMATOL
VOLUME 65, NUMBER 4
CHEMICAL PEELS
Key points
d
J AM ACAD DERMATOL
OCTOBER 2011
shown to decrease melanin formation in a dosedependent fashion using melanin assays in mouse
B16 and human melanoma cell lines.59
In clinical studies, glycolic acid peels have shown
modest benet. A dose-response trial studying the
effect of varying concentrations of glycolic acid
peels for melasma showed that 52.5% glycolic acid
applied for 3 minutes led to clinical improvement,
whereas lower concentrations did not.60 Another
open study performed in Indian females with melasma treated with sun protection involved the use
of 10% glycolic acid lotion nightly for 2 weeks
followed by monthly 50% glycolic acid facial peels
for 3 months.61 The authors found that patients with
mixed or epidermal melasma showed a decrease in
MASI score by the end of the study (level of
evidence, II-iii).
Glycolic acid has also been examined as an
adjunct to other topical treatments. When used in
combination with a modied Kligman-Willis formula
(5% hydroquinone 1 0.05% tretinoin 1 1% hydrocortisone acetate), it was shown to decrease the
MASI score by 79.9%, but the topical formula
performed almost as well when used alone in this
study, showing a 63.1% decrease in MASI score.62
Side effects in this study included erythema and
desquamation, and two patients developed postinflammatory hyperpigmentation (level of evidence,
II-iii). A similar trial evaluated patients with epidermal melasma treated with azelaic acid plus adapalene with half of the group additionally treated with
glycolic acid peels of increasing concentrations every 2 weeks.63 The investigators found that the group
treated with peels in addition to topicals had an 83%
decrease in MASI scores as compared to a 69%
decrease in the group using topicals alone. Glycolic
acid has also been studied as an adjunct to hydroquinone in a split-face trial where the authors
found no additional benefit to chemical peeling in
terms of Mexameter readings, reduction in MASI
scores, or blinded physician global assessments.64
Pretreatment with hydroquinone 2% for 2 weeks
before performing a glycolic acid peel has been
shown to enhance improvement when compared to
peels alone.65
Based on the current evidence, glycolic acid peels
are best used judiciously and as adjunctive therapy in
refractory cases of epidermal melasma. The evidence
that they are effective is mixed.
Lactic acid peels have shown some benet in
patients with epidermal melasma, with MASI scores
decreasing by almost 57% in Fitzpatrick skin phototype IV patients with no relapse seen at the 6-month
follow-up visit in a trial that was not controlled or
split-faced in design66 (level of evidence, II-iii).
J AM ACAD DERMATOL
J AM ACAD DERMATOL
OCTOBER 2011
J AM ACAD DERMATOL
VOLUME 65, NUMBER 4
J AM ACAD DERMATOL
OCTOBER 2011
First-line
Adjunctive treatment
Second-line
Third-line
Alternative agents
(strength of recommendation)
It is recommended that all patients use regular broad-spectrum photoprotection and practice sun avoidance.
treatments, laser and light therapies should be considered third-line treatments in severe refractory
patients who have not responded to topical preparations or chemical peels and who are willing to
accept the risks of these procedures.
ON THE HORIZON
Because no panacea for melasma has yet been
found, investigators continue to search for novel
inhibitors of melanin synthesis. Several new compounds are being studied as possible treatments of
melasma. Rucinol, a derivative of resorcinol that
inhibits tyrosinase and TRP-1 in a dose-dependent
manner in B16 mouse melanoma cells, has been
shown in a vehicle-controlled, split-face, doubleblind randomized trial to have a modest effect on
epidermal and mixed melasma lesions in patients
with Fitzpatrick skin phototypes III to V.85
Interestingly, broad-spectrum sun protection alone
used on the control side also showed a significant
benefit (level of evidence, I).
Tranexamic acid, also known as trans-4-aminomethylcyclohexanecarboxylic acid, is a plasmin inhibitor and lysine analog that has been shown to
prevent UV-induced pigmentation in guinea pigs.86
In keratinocytes, it prevents the binding of plasminogen to keratinocytes, which leads to less free
arachidonic acid and subsequent decreased production of prostaglandins. This in turn leads to a
decrease in tyrosinase activity in melanocytes. Of
note, topical tranexamic acid can cause allergy or
irritation, so newer liposomal delivery systems have
been created to improve tolerability. Intradermal
tranexamic acid injections have been investigated in
100 patients with Fitzpatrick skin phototypes IV to VI
and mixed or dermal melasma.87 Investigators found
that changes in MASI were statistically significant
(mean MASI 13.22 at baseline compared to 7.57 after
12 weeks of weekly injections), but clinically significant improvement was not seen until 4 weeks of
treatment. No long-term follow-up was performed
(level of evidence, II-iii).
J AM ACAD DERMATOL
VOLUME 65, NUMBER 4
J AM ACAD DERMATOL
OCTOBER 2011
J AM ACAD DERMATOL
76.
77.
78.
79.
80.
81.
82.
83.
84.
85.
86.
87.
88.
89.
J AM ACAD DERMATOL
OCTOBER 2011
Appendix. US Preventive Services Task Force levels of evidence for grading clinical trials1
Level of evidence
I
II-i
II-ii
II-iii
III
IV
Strength of recommendations
A
B
C
D
E
Quality of evidence